


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

What is claimed is:

1. (Previously Presented) A compound of formula (I):



(I)

wherein:


R<sup>1</sup> represents hydrogen, C<sub>1-4</sub>alkyl, -CH<sub>2</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CO<sub>2</sub>C<sub>1-2</sub>alkyl, or -CH<sub>2</sub>CONR<sup>7</sup>R<sup>8</sup>;

R<sup>2</sup> and R<sup>3</sup> independently represent hydrogen, -C<sub>1-6</sub>alkyl, -C<sub>1-3</sub>alkylCN, -C<sub>1-3</sub>alkylCO<sub>2</sub>H, -C<sub>1-4</sub>alkylOC<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylS(O)<sub>n</sub>C<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylINR<sup>10</sup>R<sup>11</sup>, -C<sub>1-3</sub>alkylINCO<sub>2</sub>C<sub>1-4</sub>alkyl, -C<sub>1-3</sub>alkylCONR<sup>7</sup>R<sup>8</sup>, -C<sub>1-3</sub>alkylCO<sub>2</sub>C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylCOC<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylCON(R<sup>8</sup>)C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylINCO<sub>2</sub>C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylINCOC<sub>0-2</sub>alkylR<sup>9</sup> or -C<sub>0-2</sub>alkylR<sup>9</sup>, with the proviso that one of R<sup>2</sup> and R<sup>3</sup> is hydrogen and the other is a substituent other than hydrogen;

n is an integer between 0 and 2;

R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a morpholino ring;

R<sup>6</sup> represents a group selected from:



wherein  $T_1$  and  $T_2$  independently represent  $\text{CH}_2$ ,  $\text{NH}$ ,  $\text{S}$  or  $\text{O}$  with the proviso that when one of  $T_1$  or  $T_2$  represents  $\text{NH}$ ,  $\text{S}$  or  $\text{O}$  the other represents  $\text{CH}_2$ ;

$M$  represents  $\text{CH}_3$ ,  $-\text{OH}$  or  $=\text{O}$ ;

$V$  represents  $\text{CH}$  or  $\text{N}$ ;

$W$  represents  $\text{H}$ ,  $\text{CH}_3$ ,  $\text{Cl}$  or  $\text{F}$ ;

$X$  represents  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{F}$  or  $-\text{CH}_3$ ;

$Y$  represents  $\text{CH}_3$  or  $\text{CF}_3$ ;


$Z$  represents  $-\text{CH}_3$  or  $\text{F}$ ;

$R^7$  and  $R^8$  are independently hydrogen,  $\text{C}_{1-4}$ alkyl or together with the  $\text{N}$  atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ ;


$R^{10}$  and  $R^{11}$  independently represent  $\text{C}_{1-4}$ alkyl or together with the  $\text{N}$  atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ ;

$R^9$  represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ , each of which is optionally substituted by 0-2 groups selected from:  $\text{C}_{1-3}$ alkyl or halogen; or pharmaceutically acceptable derivatives thereof.

2. (Original) A compound of formula (I) as claimed in claim 1 wherein R<sup>1</sup> represents hydrogen, methyl, -CH<sub>2</sub>CO<sub>2</sub>C<sub>1-2</sub>alkyl, or -CH<sub>2</sub>CONR<sup>7</sup>R<sup>8</sup>.
3. (Previously Presented) A compound of formula (I) as claimed in claim 1 wherein R<sup>2</sup> and R<sup>3</sup> independently represent -C<sub>1-6</sub>alkyl, -C<sub>1-3</sub>alkylCN, -C<sub>1-4</sub>alkylOC<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylS(O)<sub>n</sub>C<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylNR<sup>10</sup>R<sup>11</sup>, -C<sub>1-3</sub>alkylCONR<sup>7</sup>R<sup>8</sup>, -C<sub>1-3</sub>alkylCO<sub>2</sub>C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylCON(R<sup>8</sup>)C<sub>0-2</sub>alkylR<sup>9</sup> or -C<sub>0-2</sub>alkylR<sup>9</sup>, with the proviso that one of R<sup>2</sup> and R<sup>3</sup> is hydrogen and the other is a substituent other than hydrogen.
4. (Previously Presented) A compound of formula (I) as claimed in claim 3 wherein R<sup>3</sup> represents hydrogen.
5. (Currently Amended) A compound of formula (I) as claimed in claim 1 wherein R<sup>6</sup> represents a group selected from:



6. (Original) A compound as claimed in claim 1 wherein:
  - R<sup>1</sup> represents hydrogen, methyl, -CH<sub>2</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CO<sub>2</sub>C<sub>1-2</sub>alkyl, or -CH<sub>2</sub>CONR<sup>7</sup>R<sup>8</sup>;
  - R<sup>2</sup> represents -C<sub>1-4</sub>alkyl, -CH<sub>2</sub>CO<sub>2</sub>H, -CH<sub>2</sub>OCH<sub>3</sub>, -CH(CH<sub>3</sub>)OCH<sub>3</sub>, -CH<sub>2</sub>CON(CH<sub>3</sub>)<sub>2</sub>, benzyl, -CH<sub>2</sub>CO<sub>2</sub>-benzyl, -CH<sub>2</sub>CO-morpholine, or -CH<sub>2</sub>-thiophene;
  - R<sup>3</sup> represents hydrogen;
  - R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a morpholino ring;
  - R<sup>6</sup> represents a group selected from:



wherein W represents H, Cl or F;

X represents Cl, Br, F or -CH<sub>3</sub>;

Y represents CH<sub>3</sub> or CF<sub>3</sub>;

Z represents -CH<sub>3</sub> or F; and

R<sup>7</sup> and R<sup>8</sup> are independently hydrogen or methyl.


7. (Cancelled)

8. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutical carrier and/or excipient.

9. (Cancelled)

10. (Currently Amended) A method of treating a patient suffering from a condition susceptible to amelioration by a thrombin inhibitor, wherein said condition is selected from myocardial infarction, unstable angina, prothrombotic sequelae associated with myocardial infarction or heart failure, pulmonary embolism, deep vein thrombosis, and thromboembolic events associated with atrial fibrillation, comprising administering a therapeutically effective amount of a compound according to claim 1.

11. (Currently Amended) A process for preparing a compound of formula (I)



(I)

including pharmaceutically acceptable derivatives thereof, wherein:


R<sup>1</sup> represents hydrogen, C<sub>1-4</sub>alkyl, -CH<sub>2</sub>CO<sub>2</sub>H, -CH<sub>2</sub>CO<sub>2</sub>C<sub>1-2</sub>alkyl, or -CH<sub>2</sub>CONR<sup>7</sup>R<sup>8</sup>;

R<sup>2</sup> and R<sup>3</sup> independently represent hydrogen, -C<sub>1-6</sub>alkyl, -C<sub>1-3</sub>alkylCN, -C<sub>1-3</sub>alkylCO<sub>2</sub>H, -C<sub>1-4</sub>alkylOC<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylS(O)<sub>n</sub>C<sub>1-4</sub>alkyl, -C<sub>1-4</sub>alkylNR<sup>10</sup>R<sup>11</sup>, -C<sub>1-3</sub>alkylNCO<sub>2</sub>C<sub>1-4</sub>alkyl, -C<sub>1-3</sub>alkylCONR<sup>7</sup>R<sup>8</sup>, -C<sub>1-3</sub>alkylCO<sub>2</sub>C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylCOC<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylCON(R<sup>8</sup>)C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylNCO<sub>2</sub>C<sub>0-2</sub>alkylR<sup>9</sup>, -C<sub>1-3</sub>alkylNCOC<sub>0-2</sub>alkylR<sup>9</sup> or -C<sub>0-2</sub>alkylR<sup>9</sup>, with the proviso that one of R<sup>2</sup> and R<sup>3</sup> is hydrogen and the other is a substituent other than hydrogen;

n is an integer between 0 and 2;

R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a morpholino ring;

R<sup>6</sup> represents a group selected from:



wherein  $T_1$  and  $T_2$  independently represent  $\text{CH}_2$ ,  $\text{NH}$ ,  $\text{S}$  or  $\text{O}$  with the proviso that when one of  $T_1$  or  $T_2$  represents  $\text{NH}$ ,  $\text{S}$  or  $\text{O}$  the other represents  $\text{CH}_2$ ;

$M$  represents  $\text{CH}_3$ ,  $-\text{OH}$  or  $=\text{O}$ ;

$V$  represents  $\text{CH}$  or  $\text{N}$ ;

$W$  represents  $\text{H}$ ,  $\text{CH}_3$ ,  $\text{Cl}$  or  $\text{F}$ ;

$X$  represents  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{F}$  or  $-\text{CH}_3$ ;

$Y$  represents  $\text{CH}_3$  or  $\text{CF}_3$ ;



$Z$  represents  $-\text{CH}_3$  or  $\text{F}$ ;

$R^7$  and  $R^8$  are independently hydrogen,  $\text{C}_{1-4}$ alkyl or together with the  $\text{N}$  atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ ;

$R^{10}$  and  $R^{11}$  independently represent  $\text{C}_{1-4}$ alkyl or together with the  $\text{N}$  atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ ;

$R^9$  represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from  $\text{O}$ ,  $\text{N}$  or  $\text{S}$ , each of which is optionally substituted by 0-2 groups selected from:  $\text{C}_{1-3}$ alkyl or halogen;

which comprises reacting a compound of formula (II) with a compound of formula (III):



wherein T is a halide.